Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-26 @ 12:05 AM
Study NCT ID:
NCT05296694
Status:
COMPLETED
Last Update Posted:
2023-02-01
First Post:
2022-03-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Mortality Predictors in Coronary Care in Turkey
Sponsor:
Afyonkarahisar Health Sciences University
Organization:
Study Overview
Official Title:
Predictors of In-hospital MORtality in CORonary Care Patients in TURKey
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MORCOR-TURK
Brief Summary:
This study was undertaken to investigate and document the mortality rates and predictors in coronary care unit (CCU) patients in Turkey.
It is designed to be a multicenter, observational, cross-sectional, and descriptive study. It will be conducted in 50 centers in 12 regions of Turkey. The study does not include any interventional or treatment procedures.
At the end of the study, clinicians will have up-to-date information about predictors of mortality in CCU patients.
It is designed to be a multicenter, observational, cross-sectional, and descriptive study. It will be conducted in 50 centers in 12 regions of Turkey. The study does not include any interventional or treatment procedures.
At the end of the study, clinicians will have up-to-date information about predictors of mortality in CCU patients.
Detailed Description:
The MORCOR-TURK study will be conducted as a nationwide registry in 50 tertiary cardiology centers selected from each EuroStat NUTS region in Turkey according to their population sample weight, prioritizing the volume of hospitals in each region. All consecutive patients admitted to the coronary care units (CCU) will be prospectively admitted during a predefined period of 1 month. The study will be conducted by cardiologists in hospitals who regularly treat cardiac patients. Led by the Cardiology Department of Kutahya Evliya Celebi Research and Training Hospital, 50 centers will be included in the study.
There has not been any large-scale epidemiological study on coronary care patients in Turkey recently. Therefore, up-to-date information in this group of patients is lacking. In particular, significant reductions in mortality and morbidity are expected, thanks to improved medical and interventional facilities. In the light of current data, the investigators designed a large-scale study to document mortality rates and predictors in CCU patients.
In this study, the investigators will include consecutive patients admitted to CCU with cardiovascular indications in all participating centers. Patients will be followed and treated by experienced cardiologists and no further experimental intervention will be planned. In the first part of the study, the investigators will record in-hospital mortality rates and try to identify the best predictors. In the second part of the MORCOR-TURK trial which will have a cohort design, the investigators will follow the successfully discharged patients for 1 year. At the end of the follow-up, investigators will assess the risk factors and predictors of cardiovascular events as secondary endpoints.
There has not been any large-scale epidemiological study on coronary care patients in Turkey recently. Therefore, up-to-date information in this group of patients is lacking. In particular, significant reductions in mortality and morbidity are expected, thanks to improved medical and interventional facilities. In the light of current data, the investigators designed a large-scale study to document mortality rates and predictors in CCU patients.
In this study, the investigators will include consecutive patients admitted to CCU with cardiovascular indications in all participating centers. Patients will be followed and treated by experienced cardiologists and no further experimental intervention will be planned. In the first part of the study, the investigators will record in-hospital mortality rates and try to identify the best predictors. In the second part of the MORCOR-TURK trial which will have a cohort design, the investigators will follow the successfully discharged patients for 1 year. At the end of the follow-up, investigators will assess the risk factors and predictors of cardiovascular events as secondary endpoints.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: